Antiviral Nirmatrelvir Tied To 26% Reduced Risk For Developing Long COVID-19, Research Suggests

Healio (3/23, Bascom) reports, “The antiviral nirmatrelvir, which is part of Paxlovid, was linked to a significant reduction in the risk for long COVID and post-acute death in patients with at least one risk factor for severe illness, according to researc...